A drug called Sac-TMT with brain radiation for lung cancer that spread to the brain
Original title: Sacituzumab Tirumotecan（Sac-TMT） and Brain Radotherapy for EGFR+ NSCLC With Brain Mets
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage test in a small number of people.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial asks if a new drug plus brain radiation can slow brain tumors.
Who this trial is for. This trial is for adults whose lung cancer spread to the brain. Their cancer has a change in the EGFR gene, and it grew after an EGFR pill. The trial tests a drug called Sac-TMT, given in a vein, along with brain radiation.
Where it stands. This trial has not reported results. It is measuring how long brain tumors stay under control. It is also checking side effects. The answers are not in yet.
What this means, and what it doesn't
What it could mean: Someone who fits this picture could ask their care team about this trial. The care team can say if it makes sense to look into. The trial team decides who can take part.
What it doesn't mean: This does not mean the drug works. A trial is a test, not proven care. Taking part is not a promise that you will be helped. It is not a cure.
Source: ClinicalTrials.gov, August 27, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.